DCGI gives nod to cancer drug for Covid-19 treatment

Sun Online Desk

10th May, 2021 11:34:31 AM printer

DCGI gives nod to cancer drug for Covid-19 treatment


The Drugs Controller General of India (DCGI) has given nod for using cancer treatment drug repurposed for Covid-19 treatment– 2-deoxy-D-glucose (2-DG) for emergency use as an adjunct therapy for hospitalized moderate to severe Covid-19 patients.

The anti-Covid-19 therapeutic application of the drug was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a Defence Research and Development Organisation (DRDO) lab, in collaboration with pharma major Dr Reddy’s Laboratories, The Statesman reported.

The drug, which comes in a sachet in powder form has to be taken orally by dissolving it in water. The drug works by accumulating in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production.

“Its selective accumulation in virally infected cells makes this drug unique. A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid-19 patients,” INMAS-DRDO said.

Based on phase II results, DCGI further permitted the Phase-III clinical trials in November 2020 which was studied over 220 subjects taken from 27 hospitals across the country.